Biogen Inc(BIIB-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low200.20
Day High206.67
Open:201.63
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
Investor Brand Network
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
Tipranks
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Omada Health, Inc. (OMDA)
StockStory
Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)
BIIB
GlobeNewswire
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
Tipranks
Analysts Conflicted on These Healthcare Names: Anteris Technologies Global Corp. (AVR), Lifecore Biomedical (LFCR) and Biogen (BIIB)
Zacks Investment Research
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout
GlobeNewswire
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Palvella Therapeutics (PVLA)
StockStory
3 Overrated Stocks Walking a Fine Line
BIIB
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Biogen Shareholders Back Board, Auditor and Pay Policies
StockStory
1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky
ORLY
Tipranks
Biogen Advances BIIB115 in Post–Gene Therapy SMA: Early Signals for Long‑Term Growth
Zacks Investment Research
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
Motley Fool
Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock.
GlobeNewswire
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
GlobeNewswire
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
Tipranks
Biogen and Denali’s BIIB122 Parkinson’s Trial Completion Sets Up Key Catalyst for Investors

Profile

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.